Drug Trial Radar · NCT00451451
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jan 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,417
Actual
Start
Jun 2007
Primary completion
Aug 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Mar 23, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for MS to get worse. Other objectives of the study are to determine the safety and tolerability of BG00012, as well as the effect it may have on tests and evaluations used to assess MS. Additionally, glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012.
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
BG00012Drug
PlaceboDrug
Glatiramer AcetateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse RateTime frame: 2 years
Locations
195 sites in 28 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Cullman, Alabama
Research Site
Huntsville, Alabama
Research Site
Phoenix, Arizona
Research Site
La Jolla, California
Research Site
Loma Linda, California
Research Site
Pasadena, California
Research Site
Sacramento, California
Research Site
Walnut Creek, California
Research Site
Boulder, Colorado
Research Site
Colorado Springs, Colorado
Research Site
Fort Collins, Colorado
Research Site
Maitland, Florida
Research Site
Miami, Florida
Research Site
Naples, Florida
Research Site
Pompano Beach, Florida
Research Site
Sarasota, Florida
Research Site
St. Petersburg, Florida
Research Site
Tallahassee, Florida
Research Site
Tampa, Florida
Research Site
Augusta, Georgia
Research Site
Columbus, Georgia
Research Site
Meridan, Idaho
Research Site
Indianapolis, Indiana
Research Site
Kansas City, Kansas
Research Site
Louisville, Kentucky
Research Site
Shreveport, Louisiana
Research Site
Baltimore, Maryland
Research Site
Boston, Massachusetts
Research Site
Clinton Township, Michigan
Research Site
Grand Rapids, Michigan
Research Site
Dover, New Hampshire
Research Site
Lebanon, New Hampshire
Research Site
Freehold, New Jersey
Research Site
Teaneck, New Jersey
Research Site
Amherst, New York
Research Site
Buffalo, New York
Research Site
Cedarhurst, New York
Research Site
Mineola, New York
Research Site
Patchogue, New York
Showing 40 of 195 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.